How to Anticoagulate Patients with Heart Failure and Cancer?
Conclusion
Anticoagulation in oncologic patients is a huge challenge, and we must always consider the risks and benefits of this management. However, with the prescription of DOACs, it becomes easier, safer, and more effective. When we individualize a patient’s therapy, according to the oncologic treatment, we can purpose the most appropriated strategy. We reinforce that, because of a high complex profile with several treatments, patients must be reevaluated periodically. In this way, we will further good medical practice.
[…]
Comments are moderated by the editorial team before publication. Discussions should be evidence-based and use scientific language. Conflicts of interest should be declared.